Biomaterial composition and stiffness as decisive properties of 3D bioprinted constructs for type II collagen stimulation.

Gelatin methacrylate (GelMA) and hyaluronic acid methacrylate (HAMA) are frequently used biomaterials for 3D bioprinting, with individual well-established material characteristics. To identify an ideal combination of GelMA and HAMA for chondrogenesis, a novel, primary human chondrocyte COL2A1-Gaussia luciferase reporter system (HuCol2gLuc) was developed. With this non-destructive, high-throughput temporal assay, Gaussia luciferase is secreted from the cells and used as a proxy for measuring type II collagen production.

[Cavinton Comforte in the correction of vascular cognitive disorders].

Aim: To study the effect of cavinton comforte (CC) on the severity of cognitive impairment and motor awkwardness in patients with chronic brain ischemia (HIGM).

Material And Methods: There were 30 patients (8 men, 22 women) aged 50-65 years (61.6±4.

[Age dynamics of cognitive functions in persons 50-85 years].

The paper presents original study results of cognitive changes associated with aging in the absence of neurodegenerative, vascular and other significant for cognition disorders in period from 50 to 85 years. It was shown that aging is associated with moderate memory decrease predominantly because of retrieval deficit but not acquisition insufficiency. It was also shown that aging is associated with non-severe executive dysfunction (lack of planning and control).

[The role of spiral computed tomography in planning the surgical interventions for non-organ retroperitoneal tumors].

The surgical operation is a principal and in most cases a solitary treatment for non-organ retroperitoneal tumors. High risk of recurrence, aptitude to large local extension dictates necessity of individual surgical plan. An equality of approach is excluded.

[Neuromidin in mixed vascular and Alzheimer's dementia].

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer's dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group.